PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
HTI Automation: Tue 12 November 2024, 14:28
Discovery Park: Tue 17 September 2024, 10:01

Sanofi tops off venture arm, bringing fund to $750M

Dive Brief:

  • French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million.

 

  • The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. The evergreen fund finances a variety of companies and also helps hunt for business development and acquisition opportunities for Paris-based Sanofi.

 

  • To date, Sanofi Ventures has focused mostly on biotechnology investments, with the remaining 20% of its funding going toward digital health companies. The ventures group closed 10 investments last year.

Dive Insight:

Corporate venture arms have been big players in the biotech investment market since the turn of the century, following early efforts by companies including Johnson & Johnson and Novartis. Sanofi is now making a push to be among the largest investors, with funds rivaling the $750 million in committed capital at Novartis Venture Fund.

Sanofi Ventures has invested in 50 companies, whose specialties cover the map from rare diseases and cancer to cell and gene therapy. In addition to investments from the earliest stage of a startup to later financing rounds for more well-established companies, Sanofi Ventures executives work with their companies in various ways, including sitting on corporate boards.

Along with Bayer’s impact investment arm, Sanofi most recently helped lead the Series B financing for NextPoint Therapeutics, a biotech focused on precision immuno-oncology. In the past, Sanofi Ventures has backed Kymera, which is now working with Sanofi on an autoimmune disease drug, and ReCode Therapeutics, which is developing genetic medicines for cystic fibrosis.

While the appetite of generalist investors for early-stage biotechnology has dipped recently, Sanofi isn’t alone in preparing for more investment in the future. Last year, Atlas Venture, Forbion, Third Rock Ventures and Arch Venture Partners all raised new funds they expect to use to further finance biotechnology companies.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Eclateral 30 October 2023, 15:34
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40
Biosynth: Tue 1 October 2024, 13:25